Middleweight phenom Igor Cavalcanti returned to Dana White’s “Contender Series” just a few weeks back, securing a UFC contract with his 98-second destruction of Oscar Ravello at the promotion’s Meta Apex facility in Las Vegas. Unfortunately, the Brazilian’s debut has been put on hold after Cavalcanti tested positive for 19-Norandrosterone following a drug test administered by Nevada State Athletic Commission (NSAC).
So what happened?
“Igor’s previous nandrolone use was part of a medical treatment following
a right knee injury involving a medial meniscus tear and cartilage damage,” Cavalcanti’s manager, Lucas Lutkus, told MMA Junkie. “According to his physician’s medical report, he received three intramuscular injections of 25 mg between February 21 and March 7, 2026, to support muscle recovery and knee stability. At the time, Igor was preparing for a fight in Europe and had no knowledge that he would be competing in the UFC approximately six months later.”
Prior to his second stint on “Contender Series” program, Cavalcanti score a first-round technical knockout victory over Marek Jakimowicz at FNC 31: “Barbir vs. Ilic” on May 30 in Belgrade.
“It is important to emphasize that Igor had previously disclosed his nandrolone use to the UFC and made no attempt to conceal the treatment,” Lutkus added. “All In Sports Management began representing Igor in June 2026, after the treatment had concluded. Since becoming aware of the situation, we have worked closely with Igor and his medical team to gather the relevant documentation and remain fully committed to transparency and cooperation throughout the process.”
Cavalcanti, who stumbled in his first attempt to clear the “Contender Series” hurdle, will remain under temporary suspension until a future NSAC hearing is called to evaluate his case. The 29-year-old Brazilian is 14-2 in his MMA career with 11 knockouts and three submissions.













